SIRT1 and acute myeloid leukemia: In acute myeloid leukemia (AML), HO-1 has also been described to prevent cytotoxic effects of NK by inhibiting CD48 expression, a ligand of the NK-activating receptor 2B4, through Sirt1-H3K27-dependent pathway (79).